Alaunos Therapeutics, Inc. TCRT
1.59 USD -0.12 (-7.02%)
Regular-session close
1.59 0.00 0.00%
After hours · Nov 19, 4:00 PM ET
1.56 Day range 1.70
0.72 52-week range 4.50
- YTD
- -50.77%
- 1 year
- -51.96%
News
seekingalpha.com Alaunos Therapeutics, Inc. (TCRT) Presents at UBS Global Biopharma Conference 2026 Prepared Remarks Transcript Alaunos Therapeutics, Inc. (TCRT) Presents at UBS Global Biopharma Conference 2026 Prepared Remarks Transcript
benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session Gainers Bolt Biotherapeutics (NASDAQ:BOLT) shares moved upwards by 58.8% to $6.65 during Friday's regular session. The market value of their outstanding shares is at $7.9 million. Lucid Diagnostics…
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session Gainers Disc Medicine (NASDAQ:IRON) stock moved upwards by 50.4% to $85.51 during Monday's pre-market session. The company's market cap stands at $2.1 billion. DataMEDS AI (NASDAQ:MEDS) shares moved…
benzinga.com Why is Alaunos Therapeutics Stock Trading 200% Higher on Tuesday? Alaunos Therapeutics, Inc. (NASDAQ:TCRT) stock is surging on Tuesday with a massive session volume of 191.48 million compared to the average volume of 826.167 thousand, according to Benzinga Pro data.
globenewswire.com Alaunos Therapeutics Announces Acquisition of Velaris Therapeutics Acquisition of Velaris and concurrent oversubscribed $350 million private placement positions the Company to deliver multiple proof-of-concept datasets in pulmonary arterial hypertension
prnewswire.com Paragon Labs Expands Leadership Team with Former Apogee Executives; Velaris Therapeutics Acquired by Alaunos Therapeutics, Inc. Leadership team brings proven company-building and drug development experience to Paragon following $10.9 billion acquisition of Apogee by AbbVie Velaris is the ninth company launched around…
globenewswire.com Alaunos Therapeutics, Inc. Announces Pricing of Registered Direct Offering priced at-the-market under Nasdaq rules Alaunos Therapeutics announces pricing of a public offering of common stock and pre-funded warrants to fund working capital and general corporate purposes.
benzinga.com Why Alaunos Therapeutics Shares Are Trading Higher By Around 22%; Here Are 20 Stocks Moving Premarket Shares of Alaunos Therapeutics Inc (NASDAQ:TCRT) rose sharply in pre-market trading following a Securities and Exchange Commission filing that showed the company approved and adopted its Second…
globenewswire.com Alaunos Reports Broad Metabolic Improvements with ALN1003 in Obese Mouse Studies ALN1003 demonstrated consistent, favorable effects across key drivers of metabolic disease, including reductions in body weight and fat mass, improved insulin sensitivity, enhanced adipose function,…
globenewswire.com Alaunos Reports Preclinical ALN1003 Data Showing Effects on Insulin-Resistance-Related Biomarkers and Liver Histology in Diet-Induced Obesity Models FORT LAUDERDALE, Fla., May 18, 2026 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (Nasdaq: TCRT) today announced updated preclinical data from non-GLP diet-induced obesity (DIO) mouse studies…
prnewswire.com Valion Bio Appoints Melinda Lackey as General Counsel Seasoned Biopharmaceutical Attorney with Deep IP, Clinical-Stage, and Nasdaq Public Company Experience Joins Leadership Team SAN ANTONIO, May 4, 2026 /PRNewswire/ -- Valion Bio, Inc. (formerly Tivic…
benzinga.com Weight Loss Data From Obese Mice Looks Promising For Alaunos Therapeutics, But Shares Drop Alaunos Therapeutics Inc. (NASDAQ: TCRT) shares are down on Monday after the company announced preclinical proof-of-concept data for its lead drug candidate, ALN1003.
globenewswire.com Alaunos Therapeutics Announces Positive Preclinical Proof-of-Concept Data for ALN1003, a Differentiated Non-Hormonal Oral Treatment for Obesity and Related Metabolic Disorders Alaunos' ALN1003 shows dose dependent weight loss, better body composition, reduced liver weight, and improved liver biomarkers in preclinical studies.
defenseworld.net Short Interest in Alaunos Therapeutics, Inc. (NASDAQ:TCRT) Drops By 14.6% Alaunos Therapeutics, Inc. (NASDAQ: TCRT - Get Free Report) saw a significant decline in short interest in January. As of January 30th, there was short interest totaling 44,597 shares, a decline of…
defenseworld.net Alaunos Therapeutics (NASDAQ:TCRT) Trading 3.1% Higher – What’s Next? Alaunos Therapeutics, Inc. (NASDAQ: TCRT - Get Free Report) was up 3.1% during mid-day trading on Wednesday. The company traded as high as $3.00 and last traded at $3.00. Approximately 16,982 shares…
globenewswire.com Alaunos Therapeutics Announces $2.0 Million Registered Direct Offering HOUSTON, June 23, 2025 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (Nasdaq: TCRT) (the “Company”) today announced that it has entered into a definitive agreement with certain investors (the “SPA”)…
globenewswire.com PMGC Capital LLC Urges Alaunos Therapeutics (NASDAQ: TCRT) to Accept Term Sheet from Leading Wall Street Bank Behind Many Leading Crypto Strategies NEWPORT BEACH, Calif., June 18, 2025 (GLOBE NEWSWIRE) -- PMGC Capital LLC (“PMGC Capital”), a wholly owned subsidiary of PMGC Holdings Inc. (NASDAQ: ELAB), today issued a public statement urging…
globenewswire.com PMGC Capital LLC, a Subsidiary of PMGC Holdings Inc. (Nasdaq: ELAB), To File Schedule 13D Reporting 5.09% Stake in Alaunos Therapeutics, Inc. (Nasdaq: TCRT) NEWPORT BEACH, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- PMGC Capital LLC (“PMGC Capital,” “we,” “our,” or “us”), a wholly owned subsidiary of PMGC Holdings Inc. (Nasdaq: ELAB), today announced its…
investorplace.com Why Is Alaunos Therapeutics (TCRT) Stock Up 37% Today? Alaunos Therapeutics (NASDAQ: TCRT ) stock is up on Monday despite a lack of news from the clinical-stage oncology-focused cell therapy company. There are no new press releases or filings with the…
investorplace.com Why Is Alaunos Therapeutics (TCRT) Stock Up 14% Today? Alaunos Therapeutics (NASDAQ: TCRT ) stock is heading higher on Tuesday following the release of the clinical-stage oncology-focused cell therapy company's Q3 earnings report. The Alaunos…
globenewswire.com Alaunos Therapeutics Announces Third Quarter 2023 Financial Results, Phase 1 Clinical Data and Continued Exploration of Strategic Alternatives HOUSTON, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), today announced financial results for the third quarter ended September 30, 2023. As…
zacks.com Alaunos (TCRT) to Wind Down Sole Clinical Study, Stock Dips 65% Due to a lack of funding needs, Alaunos (TCRT) decides to end its only clinical study. The company will instead focus on its hunTR TCR discovery platform and explore broad strategic alternatives.
